Translating translation into patient benefit for atopic eczema

This review considers, in the context of British Skin Foundation (BSF)‐funded translational research into atopic eczema conducted in Newcastle, the complex interactions between clinical and non‐clinical scientists in both academia and industry and how this may have impacted on clinical care. However, research in individual centres does not occur in isolation and clinically relevant outcomes from collaborative research are increasingly supported through regional and national networks. This is illustrated by our trial of azathioprine in adults with atopic eczema conducted across centres in the North East of England that employed pharmacogenetic dosimetry. Correspondingly the formation of a UK Translational Network for Translational Research in Dermatology (UK TREND) has facilitated the development of a UK‐wide network to support atopic eczema projects based on an e‐Delphi prioritisation exercise.